3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
6
Neuroblastoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Ovarian Neoplasms
2
Myelodysplastic Syndromes
2
Fallopian Tube Neoplasms
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Congenital Abnormalities
1
Interventions
Temozolomide
64
Radiotherapy
53
Filgrastim
28
Carboplatin
24
Etoposide
20
Irinotecan
17
Vincristine
16
Cyclophosphamide
16
Cisplatin
15
Carmustine
14
Peripheral Blood Stem Cell Transplantation
13
Magnetic Resonance Spectroscopy
12
Bevacizumab
12
Thiotepa
11
Thalidomide
11
Chemotherapy, Adjuvant
11
Methotrexate
10
Paclitaxel
9
Granulocyte Colony-Stimulating Factor
9
etoposide phosphate
8
Surgical Procedures, Operative
8
Procarbazine
8
Ifosfamide
8
sargramostim
7
Topotecan
7
O(6)-benzylguanine
7
Lomustine
7
Busulfan
7
Radiation
6
Melphalan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Central Nervous System Neoplasms
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts